Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial

Melanie Schmidt, Nadja Pfetzer, Micheal Schwab, I Strauss, Ulrike KämmererNutrition 2011 · DOI

Abstract

These pilot data suggest that a KD is suitable for even advanced cancer patients. It has no severe side effects and might improve aspects of quality of life and blood parameters in some patients with advanced metastatic tumors.

Introduction

Most cancer cells exhibit a metabolic quirk known as the Warburg Effect: they depend heavily on glucose fermentation for energy, even when oxygen is plentiful. While healthy tissues can pivot to burning fatty acids and ketone bodies, many tumors lack this metabolic flexibility. This creates a potential therapeutic window: by "starving" the body of glucose through a ketogenic diet (KD), one might theoretically stress the tumor while nourishing the patient.

However, significant concerns exist regarding whether advanced cancer patients—often suffering from cachexia (severe weight loss) and fatigue—can tolerate such a restrictive regimen. There are also fears that a high-fat diet might dangerously elevate cholesterol or lipid levels in a palliative setting. This pilot study investigates the feasibility, safety, and impact on Quality of Life (QoL) of a KD in patients with advanced, metastatic cancer.

Methods

The researchers conducted a prospective observational pilot study with 16 patients (12 women, 4 men) who had advanced metastatic tumors and no remaining conventional treatment options. The cohort was heterogeneous, including patients with ovarian, breast, pancreatic, and thyroid cancers.

The Intervention: Patients were restricted to less than 70g of carbohydrates per day. To facilitate adherence, they were provided with a specific "oil-protein shake" containing MCT (medium-chain triglyceride) oil and Omega-3 fatty acids to supplement their normal groceries.

Monitoring and Assessment: Metabolism was tracked via daily urinary ketone measurements. Quality of Life (QoL) was assessed every two weeks using the EORTC QLQ-C30 questionnaire. The study flow, from enrollment to final analysis, is detailed in the flow chart below.

Figure 5: Flow chart of patient enrollment, allocation, follow-up, and analysis.

Results

Feasibility and Ketosis: Of the 16 patients enrolled, 5 completed the full three-month study. Most dropouts were due to rapid disease progression or death rather than diet intolerance. Among the 11 patients who lasted at least six weeks, 6 successfully reached a stable state of ketosis.

Figure 6: Daily urinary ketone measurements showing patients who reached stable ketosis versus those who did not.

Blood Parameters and the "Lipid Myth": Contrary to concerns, the high-fat diet did not worsen blood lipid profiles. In fact, LDL cholesterol significantly decreased (from 108 to 92 mg/dl) and triglycerides also dropped, while HDL ("good") cholesterol remained stable. Blood urea levels increased, reflecting the metabolic shift toward protein and fat utilization.

Quality of Life: While physical functioning scores naturally declined due to the course of advanced cancer, emotional functioning improved and insomnia decreased significantly in the evaluable group. Patients reported a "mild euphoria" or psychological benefit from taking an active role in their treatment.

Discussion

This pilot study demonstrates that a ketogenic diet is feasible and safe even in end-stage cancer patients. While patients lost an average of 2kg, this was often attributed to the loss of edema or intentional weight loss in overweight individuals, rather than worsening cachexia.

Limitations: The small, heterogeneous sample size prevents definitive conclusions regarding specific tumor types. Furthermore, without a control group, the "placebo effect" of intensive nutritional counseling cannot be entirely ruled out.

Future Directions: Future research should focus on randomized controlled trials to isolate metabolic effects, earlier interventions to potentially enhance standard therapies like chemotherapy, and identifying specific cancer genotypes most susceptible to glucose restriction.

Summary updated

Abstract

These pilot data suggest that a KD is suitable for even advanced cancer patients. It has no severe side effects and might improve aspects of quality of life and blood parameters in some patients with advanced metastatic tumors.
BibTeX
@inproceedings{schmidt2011effects,
  author = {Melanie Schmidt and Nadja Pfetzer and Micheal Schwab and I Strauss and Ulrike Kämmerer},
  title = {{Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial}},
  booktitle = {Nutrition},
  year = {2011},
  doi = {10.1186/1743-7075-8-54},
}
Figure